IN2015DN02577A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN02577A IN2015DN02577A IN2577DEN2015A IN2015DN02577A IN 2015DN02577 A IN2015DN02577 A IN 2015DN02577A IN 2577DEN2015 A IN2577DEN2015 A IN 2577DEN2015A IN 2015DN02577 A IN2015DN02577 A IN 2015DN02577A
- Authority
- IN
- India
- Prior art keywords
- conjugates
- specific
- maytansines
- peptide
- processes
- Prior art date
Links
- 239000000562 conjugate Substances 0.000 abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 1
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717743P | 2012-10-24 | 2012-10-24 | |
| PCT/GB2013/052662 WO2014064424A1 (en) | 2012-10-24 | 2013-10-11 | Drug-protein conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN02577A true IN2015DN02577A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-09-11 |
Family
ID=49488609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2577DEN2015 IN2015DN02577A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2012-10-24 | 2013-10-11 |
Country Status (19)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA38496B2 (fr) | 2013-03-15 | 2021-01-29 | Regeneron Pharma | Molécules biologiquement actives, leurs conjugués, et utilisations thérapeutiques |
| WO2014194030A2 (en) * | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| CA2921412C (en) | 2013-08-26 | 2024-05-28 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| ES2792598T3 (es) * | 2014-05-23 | 2020-11-11 | Novartis Ag | Métodos para preparar conjugados a partir de proteínas que contienen disulfuro |
| HK1231367A1 (zh) * | 2014-06-02 | 2017-12-22 | Regeneron Pharmaceuticals, Inc. | 抗體藥物偶聯物、試劑和製備方法及其治療用途 |
| KR20170071485A (ko) | 2014-10-14 | 2017-06-23 | 폴리테릭스 리미티드 | Peg의 일부를 포함하는 이탈기를 포함하는 시약을 사용한, 펩티드 또는 단백질의 접합방법 |
| GB2531715A (en) * | 2014-10-24 | 2016-05-04 | Polytherics Ltd | Novel drug conjugates |
| EP3220956B1 (en) * | 2014-10-24 | 2023-08-09 | Abzena (UK) Limited | Conjugates and conjugating reagents |
| WO2016160615A1 (en) | 2015-03-27 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| EP3319936A4 (en) | 2015-07-12 | 2019-02-06 | Suzhou M-conj Biotech Co., Ltd. | BRIDGE LINKER FOR CONJUGATING CELL BINDING MOLECULES |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| EP3331569A1 (en) * | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
| MX390630B (es) | 2016-01-25 | 2025-03-21 | Regeneron Pharma | Derivados de maitansinoide, conjugados de los mismos y metodos de uso. |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| JP7038663B2 (ja) | 2016-04-14 | 2022-03-18 | ポリセリックス・リミテッド | 環中に少なくとも２個の（－ｃｈ２－ｃｈ２－０－）単位を含むリンカーを含むコンジュゲート及びコンジュゲート試薬 |
| GB201608936D0 (en) | 2016-05-20 | 2016-07-06 | Polytherics Ltd | Novel conjugates and novel conjugating reagents |
| EP4282434A3 (en) | 2016-06-06 | 2024-03-06 | Abzena (UK) Limited | Antibodies, uses thereof and conjugates thereof |
| GB201614162D0 (en) | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| GB201615725D0 (en) * | 2016-09-15 | 2016-11-02 | Polytherics Ltd | Novel cytotoxic agents and conjugates thereof |
| NZ752394A (en) | 2016-11-14 | 2021-07-30 | Hangzhou Dac Biotech Co Ltd | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
| US10864279B2 (en) | 2016-12-16 | 2020-12-15 | Industrial Technology Research Institute | Linker-drug and antibody-drug conjugate (ADC) employing the same |
| WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
| CN114040778A (zh) | 2019-06-29 | 2022-02-11 | 杭州多禧生物科技有限公司 | 一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法 |
| US11918649B2 (en) | 2019-09-18 | 2024-03-05 | Molecular Templates, Inc. | PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds |
| AU2021337687A1 (en) | 2020-09-04 | 2023-03-23 | Novarock Biotherapeutics, Ltd. | Nectin-4 antibodies and uses thereof |
| CA3213295A1 (en) | 2021-03-17 | 2022-09-22 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
| CN117147824A (zh) * | 2022-05-29 | 2023-12-01 | 菲鹏生物股份有限公司 | 一种抗体缀合物及其应用 |
| CN119161461A (zh) * | 2023-06-19 | 2024-12-20 | 广东菲鹏生物有限公司 | 标记Fab抗体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| NZ547633A (en) * | 2003-11-06 | 2010-08-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| EP1940470B1 (en) * | 2005-09-26 | 2013-04-17 | Medarex, Inc. | Antibody-drug conjugates and their use |
| JP5727786B2 (ja) * | 2007-10-19 | 2015-06-03 | シアトル ジェネティクス，インコーポレーテッド | Ｃｄ１９結合性物質およびその使用 |
| JP2011523628A (ja) * | 2008-04-30 | 2011-08-18 | イミュノジェン・インコーポレーテッド | 有効なコンジュゲートおよび親水性リンカー |
| WO2010100430A1 (en) | 2009-03-04 | 2010-09-10 | Polytherics Limited | Conjugated proteins and peptides |
| AR078471A1 (es) * | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
| SG11201407600UA (en) * | 2012-06-19 | 2014-12-30 | Polytherics Ltd | Novel process for preparation of antibody conjugates and novel antibody conjugates |
-
2012
- 2012-04-24 NO NO14172620A patent/NO2789793T3/no unknown
-
2013
- 2013-10-11 BR BR112015008311A patent/BR112015008311A2/pt not_active Application Discontinuation
- 2013-10-11 RU RU2015119557A patent/RU2015119557A/ru not_active Application Discontinuation
- 2013-10-11 AU AU2013336410A patent/AU2013336410B2/en active Active
- 2013-10-11 KR KR1020157009803A patent/KR20150085808A/ko not_active Withdrawn
- 2013-10-11 US US14/437,571 patent/US20150283259A1/en not_active Abandoned
- 2013-10-11 CN CN201380055945.7A patent/CN104755106B/zh active Active
- 2013-10-11 CA CA2884359A patent/CA2884359A1/en not_active Abandoned
- 2013-10-11 EP EP13783360.4A patent/EP2911696B1/en active Active
- 2013-10-11 WO PCT/GB2013/052662 patent/WO2014064424A1/en active Application Filing
- 2013-10-11 JP JP2015538561A patent/JP6328649B2/ja active Active
- 2013-10-11 HU HUE13783360A patent/HUE037604T2/hu unknown
- 2013-10-11 DK DK13783360.4T patent/DK2911696T3/en active
- 2013-10-11 MX MX2015005124A patent/MX2015005124A/es unknown
- 2013-10-11 SG SG11201501955VA patent/SG11201501955VA/en unknown
- 2013-10-11 ES ES13783360.4T patent/ES2652513T3/es active Active
- 2013-10-11 IN IN2577DEN2015 patent/IN2015DN02577A/en unknown
-
2015
- 2015-03-11 IL IL237673A patent/IL237673A0/en unknown
- 2015-03-23 ZA ZA2015/01996A patent/ZA201501996B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015119557A (ru) | 2016-12-20 |
| JP2015536329A (ja) | 2015-12-21 |
| HUE037604T2 (hu) | 2018-09-28 |
| EP2911696A1 (en) | 2015-09-02 |
| SG11201501955VA (en) | 2015-04-29 |
| US20150283259A1 (en) | 2015-10-08 |
| BR112015008311A2 (pt) | 2017-07-04 |
| HK1208186A1 (en) | 2016-02-26 |
| ES2652513T3 (es) | 2018-02-02 |
| JP6328649B2 (ja) | 2018-05-23 |
| MX2015005124A (es) | 2015-10-29 |
| CN104755106B (zh) | 2018-03-13 |
| EP2911696B1 (en) | 2017-09-20 |
| ZA201501996B (en) | 2016-01-27 |
| KR20150085808A (ko) | 2015-07-24 |
| NO2789793T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2018-01-27 |
| CN104755106A (zh) | 2015-07-01 |
| IL237673A0 (en) | 2015-04-30 |
| DK2911696T3 (en) | 2018-01-08 |
| AU2013336410B2 (en) | 2017-08-03 |
| CA2884359A1 (en) | 2014-05-01 |
| AU2013336410A1 (en) | 2015-04-09 |
| WO2014064424A1 (en) | 2014-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN02577A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
| PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
| MY169147A (en) | Drug-protein conjugates | |
| EA201992456A2 (ru) | Самостабилизирующиеся линкерные конъюгаты | |
| WO2013072813A3 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| MX2014013807A (es) | Conjugados enlazadores auto-estabilizantes. | |
| MX2019003214A (es) | Formulaciones de proteina de inmunoglobulina del dominio variable dual estable. | |
| GEP20227398B (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof | |
| PH12013501942A1 (en) | Antibody-drug conjugates | |
| EP3538080A4 (en) | CONJUGATION LINERS, MEDICAMENT-MOLECULE CONJUGATES TO A CELL CONTAINING THE SAME, METHODS OF PREPARING AND USING SUCH CONJUGATES WITH THE BINDERS | |
| NZ737471A (en) | Hydrophilic linkers for conjugation | |
| MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
| PH12015500390A1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| MX366813B (es) | Polipeptidos de enlace cd3. | |
| PH12018500046A1 (en) | Anti-mesothelin antibodies and immunoconjugates | |
| WO2014018673A3 (en) | Fusion proteins and methods thereof | |
| EP3013789A4 (en) | Amino acid and peptide conjugates and conjugation process | |
| IL272931A (en) | Peptide conjugates, conjugation process and their uses | |
| SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
| IL265645A (en) | Monoclonal cmet binding agents, their drug conjugates and uses thereof | |
| EP4331622A3 (en) | Integrin binding peptides and uses thereof | |
| WO2014044793A3 (en) | Cd22-binding peptides | |
| MX2015006616A (es) | Doble direccion. | |
| WO2013184614A3 (en) | Peptide conjugates for treating pain |